CN115151273A - 用于治疗和预防1型糖尿病的方法和组合物 - Google Patents

用于治疗和预防1型糖尿病的方法和组合物 Download PDF

Info

Publication number
CN115151273A
CN115151273A CN202080084253.5A CN202080084253A CN115151273A CN 115151273 A CN115151273 A CN 115151273A CN 202080084253 A CN202080084253 A CN 202080084253A CN 115151273 A CN115151273 A CN 115151273A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
insulin
variant
alpha chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080084253.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Merchant Dr Mary Morris Associates LLC
Original Assignee
American Merchant Dr Mary Morris Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Merchant Dr Mary Morris Associates LLC filed Critical American Merchant Dr Mary Morris Associates LLC
Publication of CN115151273A publication Critical patent/CN115151273A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080084253.5A 2019-12-06 2020-11-25 用于治疗和预防1型糖尿病的方法和组合物 Pending CN115151273A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944503P 2019-12-06 2019-12-06
US62/944,503 2019-12-06
PCT/US2020/062159 WO2021113136A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
CN115151273A true CN115151273A (zh) 2022-10-04

Family

ID=76222225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084253.5A Pending CN115151273A (zh) 2019-12-06 2020-11-25 用于治疗和预防1型糖尿病的方法和组合物

Country Status (12)

Country Link
US (1) US12551537B2 (https=)
EP (2) EP4623900A3 (https=)
JP (1) JP2023505190A (https=)
CN (1) CN115151273A (https=)
AR (1) AR122339A1 (https=)
AU (1) AU2020398147A1 (https=)
CA (1) CA3159054A1 (https=)
DK (1) DK4069278T3 (https=)
FI (1) FI4069278T3 (https=)
PL (1) PL4069278T3 (https=)
TW (1) TW202133876A (https=)
WO (1) WO2021113136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US20050214251A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CN106414486A (zh) * 2014-04-07 2017-02-15 赛诺菲 作为肽性双重glp‑1/胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
PL1633876T3 (pl) * 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
EP1725254A4 (en) 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
US20090023630A1 (en) 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP2015514126A (ja) 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
EP3589271A4 (en) 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
EP3418738A1 (en) 2017-06-23 2018-12-26 Klinikum rechts der Isar der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
PL3954384T3 (pl) 2017-09-08 2025-10-27 Diamyd Medical Ab Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US20050214251A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CN106414486A (zh) * 2014-04-07 2017-02-15 赛诺菲 作为肽性双重glp‑1/胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAROLIN DANIEL等: "Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope", J. EXP. MED., vol. 208, no. 7, 4 July 2011 (2011-07-04), pages 1501 - 1510 *
NOORI S. DAWOOD AL-WAILI: "Sublingual Human Insulin for Hyperglycaemia in Type I Diabetes", J PAK MED ASSOC, vol. 49, no. 7, 31 July 1999 (1999-07-31), pages 167 - 169 *
SHAUN A NGUYEN等: "Assessment of palatability of two sublingual diluents in allergic patients: a prospective pilot study", RANDOMIZED CONTROLLED TRIAL, vol. 25, no. 5, 1 September 2011 (2011-09-01), pages 342 - 345 *

Also Published As

Publication number Publication date
EP4623900A3 (en) 2025-12-10
US20230018324A1 (en) 2023-01-19
AU2020398147A1 (en) 2022-06-02
CA3159054A1 (en) 2021-06-10
EP4623900A2 (en) 2025-10-01
WO2021113136A1 (en) 2021-06-10
TW202133876A (zh) 2021-09-16
JP2023505190A (ja) 2023-02-08
DK4069278T3 (da) 2025-06-30
EP4069278A1 (en) 2022-10-12
AR122339A1 (es) 2022-09-07
US12551537B2 (en) 2026-02-17
PL4069278T3 (pl) 2025-10-06
EP4069278B1 (en) 2025-06-11
EP4069278A4 (en) 2024-01-10
FI4069278T3 (fi) 2025-07-16

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
US5424286A (en) Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20030158101A1 (en) Glucagon-like peptide-2 and its therapeutic use
ZA200109925B (en) GLP-1 as a diagnostic test to determine beta-cell function and the presence of the condition of IGT and type-II diabetes.
JP2017522368A (ja) グルカゴン受容体アンタゴニスト抗体を使用する１型糖尿病の治療方法
CN115151273A (zh) 用于治疗和预防1型糖尿病的方法和组合物
US6274549B1 (en) Treatment of type 1 diabetes
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
CN116847869A (zh) 用于治疗和预防1型糖尿病的方法和组合物
Brandt Synthesis and characterization of insulin receptor partial agonists as a route to improved diabetes therapy
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
CN114929258A (zh) 用于治疗2型糖尿病中的慢性肾病和糖尿病性肾病的胰高血糖素和glp-1协同激动剂
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination